Who is a suitable candidate for this injection?

Could this injection work for your hip? The short answer depends on two things: what kind of cartilage damage you have, and how much background arthritis is already present in the joint.

ChondroFiller is designed for focal, contained, full-thickness cartilage defects — specifically Grade III or IV on the standard ICRS scale — on the acetabulum or femoral head. Defect size typically falls between 2 and 4.5 cm². Most candidates reach this point because of femoroacetabular impingement (FAI), where abnormal bone contact has worn through the cartilage layer at a discrete site. The injection is not a treatment for generalised hip osteoarthritis, where damage is diffuse rather than focal.

The single most important eligibility filter

Background OA severity — graded on the Tönnis scale — acts as the decisive gate. Patients with Tönnis Grade 0 or 1 (minimal or no osteoarthritis on X-ray) have consistently achieved good-to-excellent results in published series, because the biological environment still supports progenitor-cell migration and tissue repair. At Tönnis Grade 2 or 3, where joint-space narrowing is already significant, multiple sources report uniformly poor outcomes; this level of background OA is therefore regarded as a near-absolute contraindication. Pre-assessment imaging to establish Tönnis grade is not a formality — it is the central clinical decision.

Because ChondroFiller is acellular, no cartilage biopsy or laboratory cell-culture step is required before treatment. Patients who meet the defect and OA criteria can move to the injection pathway directly, without those preparatory stages.

How the collagen scaffold repairs cartilage

The scaffold works not by delivering new cells, but by creating the conditions for the body's own repair process to take hold.

Once the liquid collagen is injected into the defect, it self-polymerises — essentially sets — within 3 to 5 minutes at body temperature, forming a soft, porous three-dimensional matrix that fills the damaged area. Think of it as a temporary framework: the collagen holds the space open and provides structural cues while the body does the rebuilding work.

Progenitor cells from the surrounding bone and soft tissue migrate into this matrix over the following weeks and months. The scaffold guides them to differentiate into chondrocyte-like cells — the cell type responsible for producing cartilage — which then lay down repair tissue as the collagen gradually resorbs and is replaced by the body's own material.

It is worth being precise about what that repair tissue is. The outcome is fibrocartilage: resilient and clinically meaningful in appropriately selected patients, but mechanically and structurally distinct from the hyaline cartilage that lines a healthy joint surface. Evidence suggests the scaffold supports the formation of useful repair tissue; it does not reliably regenerate native hyaline cartilage, and claims to that effect should be treated with caution.

Because the scaffold contains no donor or patient-derived cells, the treatment does not require a prior biopsy or a laboratory culture stage. Autologous chondrocyte implantation follows a fundamentally different pathway — harvesting cells at a first procedure, culturing them over several weeks, then re-implanting them surgically. The collagen scaffold collapses that multi-stage process into a single outpatient appointment.

Why ultrasound guidance is essential for the hip

Reaching the hip joint safely is not straightforward. The joint sits 4–8 cm beneath overlying soft tissue, and the anterior capsule — the target entry point — lies in close proximity to major neurovascular structures: the femoral artery approximately 1.9 cm medial, the femoral vein approximately 1.7 cm medial, and the femoral nerve approximately 2.3 cm lateral. The lateral circumflex femoral artery adds a further complication: its course across the anterior capsule varies between individuals and cannot be mapped reliably from surface landmarks alone.

This anatomy makes landmark-guided (blind) injection unsafe rather than merely imprecise. A 2016 systematic review by Hoeber and colleagues — drawing on 120 studies — found that landmark technique achieved accurate intra-articular placement in only 72% of hip injection attempts (95% CI 56–85%), compared with 100% (95% CI 98–100%) for image-guided approaches (p<0.0001). That roughly 28% miss rate is not a minor inaccuracy: at this depth, a misplaced needle may reach soft tissue, bursa, or a neurovascular structure that should not receive an injection at all.

For ChondroFiller specifically, placement accuracy carries an additional consequence. The collagen sets in situ — wherever it is delivered — so a misplaced injection does not simply miss the target; it wastes the full therapeutic dose as well. Accurate placement is therefore both a patient-safety requirement and a prerequisite for the treatment to work as intended. Real-time ultrasound guidance fulfils both demands simultaneously, making it standard practice for this type of deep-joint injection rather than an optional upgrade.

What the injection appointment involves

Before attending, an MRI scan is needed to confirm the defect's grade, size, and precise location — this imaging forms the clinical gate that determines whether the injection is appropriate and what volume of material will be used.

On the day, the liquid collagen is warmed to 37°C to support consistent polymerisation. The skin over the injection site is cleaned and local anaesthetic is applied to the skin and underlying tissue. No general anaesthetic is required; the entire procedure takes place in an outpatient setting.

With the patient positioned on the clinic couch, the clinician uses real-time ultrasound to guide the needle through the anterior soft tissue to the joint space — the image-guided approach described in the previous section. Once the needle tip is confirmed within the cartilage defect, the collagen is delivered through a dual-chamber syringe that keeps its two components separate until the moment of injection, combining them as they are expressed directly into the defect.

The collagen then sets in place over the next few minutes. During this brief setting phase the patient remains still to allow the scaffold to stabilise before the appointment concludes. Most patients are able to leave the clinic shortly afterwards.

Recovery: why protected loading matters and what to expect

Unlike many outpatient injections, ChondroFiller begins a biological process on the day of treatment — but the repair itself unfolds over months, and the early phase carries a specific physical constraint.

Published biomechanical data from a 2024 in-vitro study confirm that in its early phase, the collagen scaffold is not mechanically stable enough to withstand full cyclic joint loading without risking damage to the opposing cartilage surface. This is why protected weight-bearing — partial loading only — is required for the first 4–6 weeks: not as a general precaution, but as a direct response to what the material can and cannot tolerate while it integrates. Returning to full loading too soon does not merely slow healing; the evidence indicates it may actively harm the cartilage surface the treatment is designed to protect.

As the scaffold matures and repair tissue begins to consolidate — a process that published series suggest takes roughly 3–6 months — patients typically progress to low-impact activities such as cycling or swimming. Return to sport or sustained high-impact activity is broadly consistent with a 12-month timeline in published reports, reflecting the biological pace of fibrocartilage formation rather than an arbitrary milestone.

Anyone considering this pathway should plan for a long recovery arc. That honesty matters practically: patients with physically demanding jobs or competitive sporting commitments need to factor in the full timeline before committing to the treatment.

What published outcomes show — and where evidence is limited

The most directly relevant clinical evidence comes from a 2021 cohort study published in the Journal of Hip Preservation Surgery (Mazek et al.), which followed 26 adults with femoroacetabular impingement and acetabular cartilage lesions exceeding 2 cm². At 3–5 year follow-up, 17 of 21 evaluable patients — 81% — recorded good or excellent results, with MRI confirming statistically significant cartilage healing compared with pre-treatment imaging.

Functional outcome data from knee studies form the mechanism-proxy evidence base beyond that single hip cohort. Across multiple published series, IKDC scores improved by approximately 30 points over 12 months — consistently above the established minimum clinically important difference of 16.7 points. MRI-based MOCART scores in those cohorts reached 81.6 to 84.3 at one year, indicating more than 80% defect fill and good tissue integration at that timepoint. These knee data are referenced because the biological mechanism — endogenous cell migration into a collagen scaffold — is shared across joints; they do not substitute for hip-specific trial evidence.

That distinction carries weight when reading the results honestly. The hip evidence rests on a single cohort of 26 patients, with further cases described in smaller technical series. Studies available to date are predominantly manufacturer-associated, and no large independent randomised controlled trial in the hip exists; published follow-up extends to five years at most. ChondroFiller is not NHS-funded, so the pathway is self-funded throughout. Whether a larger independent trial would confirm the 81% good-or-excellent rate, narrow its confidence intervals, or reveal that outcomes differ by defect location — femoral head versus acetabulum, for instance — remains genuinely unknown. Individual suitability turns on the factors the existing evidence already identifies: defect grade, lesion size, and Tönnis status, each of which requires a formal assessment to establish.

1. [1] Arthroscopic utilization of ChondroFiller gel for the treatment of hip articular cartilage defects: a cohort study with 12- to 60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
2. [2] Controlled, randomized multicenter study to compare ChondroFiller liquid with microfracturing for focal cartilage defects of the knee. (2016). https://doi.org/10.5348/VNP05-2016-1-OA-1 https://doi.org/10.5348/VNP05-2016-1-OA-1
3. [3] Influence of cartilage defects and a collagen gel on integrity of corresponding intact cartilage: a biomechanical in-vitro study. (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z